Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 551

1.

Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.

McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, Carson P, Massie BM; I-Preserve Investigators.

J Card Fail. 2010 Feb;16(2):128-34. doi: 10.1016/j.cardfail.2009.09.007. Epub 2009 Nov 4.

PMID:
20142024
2.

Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.

Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE.

Circ Heart Fail. 2011 Sep;4(5):569-77. doi: 10.1161/CIRCHEARTFAILURE.111.962654. Epub 2011 Jun 29.

3.

Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.

von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.

J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. Epub 2007 Oct 29.

4.

Comparative value of BNP and NT-proBNP in diagnosis of heart failure.

Fonseca C, Sarmento PM, Minez A, Gonçalves E, Covas R, Dias AR, Pina MJ, Ceia F.

Rev Port Cardiol. 2004 Jul-Aug;23(7-8):979-91. English, Portuguese.

5.

Plasma N-terminal protype-B natriuretic peptide and restrictive mitral flow to risk-stratify patients with stage B heart failure.

Dini FL, Whalley G, Poppe K, Fontanive P, Rosa GM, Doughty RN, Di Bello V.

Clin Cardiol. 2009 Dec;32(12):711-7. doi: 10.1002/clc.20617.

6.

Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).

Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM.

Circ Heart Fail. 2011 Jan;4(1):27-35. doi: 10.1161/CIRCHEARTFAILURE.109.932996. Epub 2010 Nov 10.

7.

Inflammatory pathways in patients with heart failure and preserved ejection fraction.

Niethammer M, Sieber M, von Haehling S, Anker SD, Munzel T, Horstick G, Genth-Zotz S.

Int J Cardiol. 2008 Sep 16;129(1):111-7. Epub 2007 Jul 20.

PMID:
17658631
8.

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E.

Am J Cardiol. 2008 Sep 15;102(6):733-7. doi: 10.1016/j.amjcard.2008.04.048. Epub 2008 Jul 9.

PMID:
18773998
9.

Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.

Sirithunyanont C, Leowattana W, Sukumalchantra Y, Chaisupamonkollarp S, Watanawaroon S, Chivatanaporn B, Bhuripanyo K, Mahanonda N.

J Med Assoc Thai. 2003 May;86 Suppl 1:S87-95.

PMID:
12866774
11.

Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.

Corell P, Gustafsson F, Kistorp C, Madsen LH, Schou M, Hildebrandt P.

Int J Cardiol. 2007 May 2;117(3):395-402. Epub 2006 Aug 17.

PMID:
16919342
12.

Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.

Linssen GC, Rienstra M, Jaarsma T, Voors AA, van Gelder IC, Hillege HL, van Veldhuisen DJ.

Eur J Heart Fail. 2011 Oct;13(10):1111-20. doi: 10.1093/eurjhf/hfr066. Epub 2011 Jun 3.

13.

Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.

Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr.

Am Heart J. 2010 Apr;159(4):532-538.e1. doi: 10.1016/j.ahj.2010.01.005.

PMID:
20362709
14.

Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.

de Denus S, Lavoie J, Ducharme A, O'Meara E, Racine N, Sirois MG, Neagoe PE, Zhu L, Rouleau JL, White M.

Can J Cardiol. 2012 Jan-Feb;28(1):62-8. doi: 10.1016/j.cjca.2011.09.007. Epub 2011 Nov 21.

PMID:
22104539
15.

Correlates of NT-proBNP concentration in patients with essential hypertension in absence of congestive heart failure.

Toda K, Sato Y, Hara T, Hijiya K, Kaneko R, Okada T, Takatsu Y, Fujiwara H, Iwasaki T.

J Clin Lab Anal. 2010;24(1):12-6. doi: 10.1002/jcla.20366.

PMID:
20087954
16.

Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay.

Lee-Lewandrowski E, Januzzi JL, Green SM, Tannous B, Wu AH, Smith A, Wong A, Murakami MM, Kaczmarek J, Apple FS, Miller WL, Hartman K, Jaffe AS.

Clin Chim Acta. 2007 Nov-Dec;386(1-2):20-4. Epub 2007 Jul 25.

PMID:
17854790
17.

N-terminal probrain natriuretic peptide predicts adverse outcomes in acute-myocardial infarction even with preserved left ventricular ejection fraction.

Puri A, Narain VS, Mehrotra S, Dwivedi SK, Saran RK, Puri VK.

Indian Heart J. 2006 Mar-Apr;58(2):138-43.

PMID:
18989058
19.

Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.

Dini FL, Gabutti A, Passino C, Fontanive P, Emdin M, De Tommasi SM.

Int J Cardiol. 2010 Apr 30;140(3):344-50. doi: 10.1016/j.ijcard.2008.11.108. Epub 2009 Jan 6.

PMID:
19128846
20.

Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Jug B, Sebestjen M, Sabovic M, Pohar M, Keber I.

Wien Klin Wochenschr. 2009;121(21-22):700-6. doi: 10.1007/s00508-009-1269-5.

PMID:
19998011
Items per page

Supplemental Content

Write to the Help Desk